Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-160

Im pretty sure the accounts you have mentioned are made up of small retail holders, I know for a fact citicorp nominees consists of IG Markets shareholders which are all small retailers. HSBC seems to be the main culrpit however bare in mind this is from inception of the company. Alot would have unloaded after those first set of phase 2 results and the cap raise.

Although at first I wanted IXC to explore another indication after speaking with Tom I think this is a not a value driver for IXC.
Tom in the Bell Potter Investor Preso mentioned the company CUV. People should research CUV, I have conducted research on it, and like IXC is it a 1 drug company with 1 indication. Like IXC it hovered around 50 -100 mill MC leading up to Phase 3 results and only targeting EMA. It is now a 1.5 bill MC company generating annual profits and paying dividends off ONE drug. Read the forums back in 2014-2016, it literally sounds exactly like us today. Quotes like this is a phase 3 company valued at 50 mill MC lolol.

As quoted by Tom after recent discussions.....
'the only drug company on ASX that has actually registered a drug (not a diagnostic or device) for a disease in the last ten years is Clinuvel that I can think of. Everyone else has pretty much butchered their FDA approval or Phase 3 trial failed. That was (and still is) a one trick pony. If we had 2-3 drugs and 2-3 indications, we’d be burning 5x as much money and I very much doubt it lowers the risk profile of Invex, indeed it materially increases the financial risk.
I worked at Sirtex: one approved device, one disease approved - $2 Billion trade sale. Cochlear – built a massive company from one product, one indication. Clinuvel, as discussed.
Opthea – single drug Phase 3
Paradigm – single drug Phase 3'


Do you know whats funny, the exact same thing thats happening to CUV is happening to IXC, and CUV exploded once it started reporting Phase 3 data.....
$2 to as high as $40.....DYOR